Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 5.25 GBp
Change Today +0.125 / 2.44%
Volume 5.6M
RENE On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:04 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

reneuron group plc (RENE) Snapshot

Open
5.38 GBp
Previous Close
5.13 GBp
Day High
5.63 GBp
Day Low
5.13 GBp
52 Week High
05/13/15 - 5.63 GBp
52 Week Low
06/16/14 - 2.75 GBp
Market Cap
93.9M
Average Volume 10 Days
19.9M
EPS TTM
-0.0040 GBp
Shares Outstanding
1.8B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RENEURON GROUP PLC (RENE)

Related News

No related news articles were found.

reneuron group plc (RENE) Related Businessweek News

No Related Businessweek News Found

reneuron group plc (RENE) Details

ReNeuron Group plc is engaged in the research and development of stem cell technologies for therapeutic and non-therapeutic applications worldwide. Its lead therapeutic candidate is ReN001 stem cell therapy, which is in Phase II clinical trial for the treatment of patients left disabled by the effects of a stroke. The company is also developing ReN009 stem cell therapy candidate that is in Phase I clinical trial to treat critical limb ischaemia; and ReN003 stem cell therapy candidate, which is in pre-clinical trial for the treatment of retinitis pigmentosa. In addition, it develops and markets a range of stem cell lines, including ReNcell VM, a neural cell line derived from the ventral mesencephalon region of the brain; and ReNcell CX that is derived from the cerebral cortex. ReNeuron Group plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

27 Employees
Last Reported Date: 07/12/14
Founded in 1997

reneuron group plc (RENE) Top Compensated Officers

Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: 228.0K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 262.0K GBP
Compensation as of Fiscal Year 2014.

reneuron group plc (RENE) Key Developments

FDA Gives ReNeuron Approval to Start a Phase I/II Clinical Trial in the US in Retinitis Pigmentosa

ReNeuron Group plc announced that it has received regulatory approval from the US Food and Drug Administration (FDA) to commence a Phase I/II clinical trial in the US with its human Retinal Progenitor Cell (hRPC) therapy candidate for retinitis pigmentosa (RP). RP is a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying. ReNeuron's cell therapy candidate for RP has already been granted Orphan Drug Designation in both Europe and the US by the European Commission and the FDA, respectively. The Phase I/II clinical trial will be conducted at Massachusetts Eye and Ear, Boston. The trial design is an open-label, dose escalation study to evaluate the safety, tolerability and preliminary efficacy of the hRPC stem cell therapy candidate in up to 15 patients with advanced RP. Preparations for the study have commenced and ReNeuron expects the study to begin in the second half of this year.

ReNeuron Group plc Presents at UBS Global Healthcare Conference, May-18-2015

ReNeuron Group plc Presents at UBS Global Healthcare Conference, May-18-2015 . Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: John David Sinden, Founder, Chief Scientific Officer, Executive Director and Member of Scientific & Strategic Advisory Group, Olav Hellebo, Chief Executive Officer and Director.

ReNeuron Group plc Provides Final Update on the PISCES Phase I Clinical Trial of its CTX Stem Cell Therapy

ReNeuron Group plc provided a further and final update on the PISCES Phase I clinical trial of its CTX stem cell therapy for disabled stroke patients. Long term follow-up data out to at least 24 months in all patients treated in the PISCES study are being presented by the clinical team from Glasgow's Southern General Hospital on 19th April in a platform presentation at the 2015 European Stroke Organisation Conference (ESOC), taking place in Glasgow. The data are being presented ahead of submission for publication in a peer-reviewed clinical journal later this year. The company is currently conducting a UK multi-site Phase II clinical trial (PISCES II) to examine the efficacy of its CTX stem cell treatment in patients disabled by an ischaemic stroke. As a result of observed good safety profile of the treatment, the high cell dose from the PISCES study is being used in the ongoing Phase II study. As with the PISCES study, the Phase II clinical trial involves a single, one-off injection of CTX cells into the brain. Subject to patient recruitment, initial data from this study are expected around the end of the year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RENE:LN 5.25 GBp +0.125

RENE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $4.64 USD +0.06
Geron Corp $3.96 USD -0.06
International Stem Cell Corp $0.05 USD 0.00
Neuralstem Inc $1.58 USD -0.0199
Ocata Therapeutics Inc $6.74 USD +0.12
View Industry Companies
 

Industry Analysis

RENE

Industry Average

Valuation RENE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 119.0x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 118.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RENEURON GROUP PLC, please visit www.reneuron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.